Case Report: Upadacitinib in the management of refractory urticarial vasculitis
Urticarial vasculitis (UV) is a rare autoimmune condition characterized by persistent urticarial lesions with underlying small vessel leukocytoclastic vasculitis. It often presents with systemic symptoms and poses therapeutic challenges, especially in refractory cases. We report the case of a 39-yea...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1669513/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222603485478912 |
|---|---|
| author | Maan M. Almaghrabi Maan M. Almaghrabi Nadeen Kalantan Nadeen Kalantan Alhusain Alshareef Abdulhadi Jfri Abdulhadi Jfri Abdulhadi Jfri |
| author_facet | Maan M. Almaghrabi Maan M. Almaghrabi Nadeen Kalantan Nadeen Kalantan Alhusain Alshareef Abdulhadi Jfri Abdulhadi Jfri Abdulhadi Jfri |
| author_sort | Maan M. Almaghrabi |
| collection | DOAJ |
| description | Urticarial vasculitis (UV) is a rare autoimmune condition characterized by persistent urticarial lesions with underlying small vessel leukocytoclastic vasculitis. It often presents with systemic symptoms and poses therapeutic challenges, especially in refractory cases. We report the case of a 39-year-old woman who presented with recurrent episodes of widespread, painful wheals lasting more than 24 h, along with arthralgia, myalgia, blurred vision, and fatigue. Her diagnosis was confirmed by skin biopsy, and she failed multiple lines of immunosuppressive and biologic therapies, including corticosteroids, colchicine, omalizumab, dapsone, rituximab, mycophenolate mofetil, and cyclosporine. After initiating treatment with Upadacitinib 30 mg daily orally, in combination with omalizumab and dapsone, she experienced a dramatic clinical improvement within one month, with near-complete resolution of cutaneous lesions and significant relief of systemic symptoms. This case highlights the potential role of JAK inhibitors, particularly Upadacitinib, as a novel therapeutic option in managing refractory urticarial vasculitis. Further studies are needed to evaluate its long-term efficacy and safety in this context. |
| format | Article |
| id | doaj-art-3c2db8f3eb5d4efb86d270ce6b7fb9eb |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-3c2db8f3eb5d4efb86d270ce6b7fb9eb2025-08-26T04:12:48ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-08-011210.3389/fmed.2025.16695131669513Case Report: Upadacitinib in the management of refractory urticarial vasculitisMaan M. Almaghrabi0Maan M. Almaghrabi1Nadeen Kalantan2Nadeen Kalantan3Alhusain Alshareef4Abdulhadi Jfri5Abdulhadi Jfri6Abdulhadi Jfri7College of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaDivision of Dermatology, Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi ArabiaDivision of Dermatology, Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi ArabiaDepartment of Rheumatology, The Ottawa Hospital, Ottawa, ON, CanadaDivision of Dermatology, Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi ArabiaDivision of Dermatology, Department of Medicine, Ministry of the National Guard-Health Affairs, Jeddah, Saudi ArabiaCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi ArabiaKing Abdullah International Medical Research Center, Jeddah, Saudi ArabiaUrticarial vasculitis (UV) is a rare autoimmune condition characterized by persistent urticarial lesions with underlying small vessel leukocytoclastic vasculitis. It often presents with systemic symptoms and poses therapeutic challenges, especially in refractory cases. We report the case of a 39-year-old woman who presented with recurrent episodes of widespread, painful wheals lasting more than 24 h, along with arthralgia, myalgia, blurred vision, and fatigue. Her diagnosis was confirmed by skin biopsy, and she failed multiple lines of immunosuppressive and biologic therapies, including corticosteroids, colchicine, omalizumab, dapsone, rituximab, mycophenolate mofetil, and cyclosporine. After initiating treatment with Upadacitinib 30 mg daily orally, in combination with omalizumab and dapsone, she experienced a dramatic clinical improvement within one month, with near-complete resolution of cutaneous lesions and significant relief of systemic symptoms. This case highlights the potential role of JAK inhibitors, particularly Upadacitinib, as a novel therapeutic option in managing refractory urticarial vasculitis. Further studies are needed to evaluate its long-term efficacy and safety in this context.https://www.frontiersin.org/articles/10.3389/fmed.2025.1669513/fullurticarial vasculitisUpadacitinibJAK inhibitordermatologyrheumatology |
| spellingShingle | Maan M. Almaghrabi Maan M. Almaghrabi Nadeen Kalantan Nadeen Kalantan Alhusain Alshareef Abdulhadi Jfri Abdulhadi Jfri Abdulhadi Jfri Case Report: Upadacitinib in the management of refractory urticarial vasculitis Frontiers in Medicine urticarial vasculitis Upadacitinib JAK inhibitor dermatology rheumatology |
| title | Case Report: Upadacitinib in the management of refractory urticarial vasculitis |
| title_full | Case Report: Upadacitinib in the management of refractory urticarial vasculitis |
| title_fullStr | Case Report: Upadacitinib in the management of refractory urticarial vasculitis |
| title_full_unstemmed | Case Report: Upadacitinib in the management of refractory urticarial vasculitis |
| title_short | Case Report: Upadacitinib in the management of refractory urticarial vasculitis |
| title_sort | case report upadacitinib in the management of refractory urticarial vasculitis |
| topic | urticarial vasculitis Upadacitinib JAK inhibitor dermatology rheumatology |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1669513/full |
| work_keys_str_mv | AT maanmalmaghrabi casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT maanmalmaghrabi casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT nadeenkalantan casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT nadeenkalantan casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT alhusainalshareef casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT abdulhadijfri casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT abdulhadijfri casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis AT abdulhadijfri casereportupadacitinibinthemanagementofrefractoryurticarialvasculitis |